These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10955016)

  • 1. [Weight reduction, statins or fibrates? How to reach lipid goal values in diabetic patients].
    Sailer D
    MMW Fortschr Med; 2000 Jul; 142(30):30-2. PubMed ID: 10955016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid management with statins. The lower the better?
    Laufs U; Liao JK; Böhm M
    Z Kardiol; 2004 Jan; 93(1):4-9. PubMed ID: 14740235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Statins--attaining goal values--with reference to recent studies].
    Toplak H; Schallmoser K; DeCampo A
    Wien Med Wochenschr; 1999; 149(5-6):144-5. PubMed ID: 10408006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'.
    Devroey D; Velkeniers B; Duquet W; Betz W
    Int J Cardiol; 2005 May; 101(2):231-5. PubMed ID: 15882669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New studies of high dosage statins and fibrates. How is lipid lowering therapy changing? (interview by Dr. med. Dirk Einecke)].
    Klose G
    MMW Fortschr Med; 2005 Dec; 147(49-50):20. PubMed ID: 16401005
    [No Abstract]   [Full Text] [Related]  

  • 7. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lipid control in diabetic patients in Extremadura (Spain)].
    Roberto Robles N; Barroso S; Marcos G; Sánchez Muñoz-Torrero JF;
    Endocrinol Nutr; 2009 Mar; 56(3):112-7. PubMed ID: 19627723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
    Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA
    Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the most effective strategy for managing diabetic dyslipidaemia?
    Reasner CA
    Atheroscler Suppl; 2005 Sep; 6(3):21-7. PubMed ID: 16054442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hyperlipidemia: decreasing lipid values and effects of statins].
    Mathes P
    Z Kardiol; 2002; 91 Suppl 2():25-9. PubMed ID: 12436762
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Coronary heart disease prevention. Are there differences in cholesterol synthesis inhibitors?].
    Müller-Wieland D; Faust M; Schleifenbaum T; Krone W
    MMW Fortschr Med; 2000 Jul; 142(30):26-8. PubMed ID: 10955015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
    Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LDL-Cholesterol is the King.
    Goumas GS
    Angiology; 2009; 60(3):387-8. PubMed ID: 19497926
    [No Abstract]   [Full Text] [Related]  

  • 18. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS; Mikhailidis DP
    Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.